Cell- and Tissue-Based Therapy
"Cell- and Tissue-Based Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
| Descriptor ID |
D064987
|
| MeSH Number(s) |
E02.095.147
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cell- and Tissue-Based Therapy".
Below are MeSH descriptors whose meaning is more specific than "Cell- and Tissue-Based Therapy".
This graph shows the total number of publications written about "Cell- and Tissue-Based Therapy" by people in this website by year, and whether "Cell- and Tissue-Based Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 1 | 4 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell- and Tissue-Based Therapy" by people in Profiles.
-
CRISPR-mediated Sox9 activation and RelA inhibition enhance cell therapy for osteoarthritis. Mol Ther. 2024 Aug 07; 32(8):2549-2562.
-
Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T-cell therapy. Eur J Haematol. 2024 Jan; 112(1):102-110.
-
Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Br J Haematol. 2022 04; 197(1):71-75.
-
Reply to: "Cell Therapy for Huntington's Disease: Learning from Failure". Mov Disord. 2021 03; 36(3):788-789.
-
Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy". Mov Disord. 2020 11; 35(11):2120-2121.
-
A Failed Future. Mov Disord. 2020 08; 35(8):1299-1301.
-
Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020 04; 61(4):940-943.
-
Clinical Benefits of Stem Cells for Chronic Symptomatic Systolic Heart Failure: A Systematic Review of the Existing Data and Ongoing Trials. Cell Transplant. 2016 11; 25(11):1911-1923.
-
Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study. Cell Transplant. 2016; 25(9):1701-1711.
-
Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet. 2016 Jun 11; 387(10036):2412-21.